JSH-23

• Description :

  JSH-23 is an NF-κB inhibitor which inhibits NF-κB transcriptional activity with an IC50 of 7.1 μM in lipopolysaccharide (LPS) -stimulated macrophages RAW 264.7. JSH-23 inhibits nuclear translocation of NF-κB p65 without affecting IκBα degradation[1].

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H318, H400

• Target :

  NF-κB

• Type :

  Reference compound

• Related Pathways :

  NF-κB

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Metabolic Disease; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/JSH-23.html

• Purity :

  99.92

• Solubility :

  DMSO : ≥ 56 mg/mL

• Smiles :

  NC1=CC(C)=CC=C1NCCCC2=CC=CC=C2

• Molecular Formula :

  C16H20N2

• Molecular Weight :

  240.34

• Precautions :

  H302, H318, H400

• References & Citations :

  [1]Shin HM, et al. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett. 2004 Jul 30;571 (1-3) :50-4.|[2]Kumar A, et al. JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: effect on neuroinflammation and antioxidant defence. Diabetes Obes Metab. 2011 Aug;13 (8) :750-8.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  NF-κB

• CAS Number :

  [749886-87-1]